Palantir Technologies Inc. Faces Potential Volatility as Analysts Suggest Holding Position

StockInvest.us, 2 years ago

Summary

Palantir Technologies Inc. (NYSE: PLTR) is experiencing short-term selling pressure due to overbought conditions and high volatility, but the company's strong revenue growth and new contracts in the healthcare industry provide a cautiously optimistic outlook in the near term, resulting in a 'Hold' verdict for the stock.

Palantir Technical Analysis

Palantir Technologies Inc. (NYSE: PLTR) closed the last trading session at $19.80, experiencing a notable dip of 7.22% from the previous close. The stock fluctuated between $19.72 and $21.85 during the day, just shy of its 52-week high at $21.85. Despite the recent pullback, PLTR has been on an upward trend as reflected by its 50-day moving average ($16.78) and 200-day moving average ($13.28). The stock's Relative Strength Index (RSI) stands at 74, indicating that it may be overbought and could be subject to a pullback or consolidation in the near term.

The Moving Average Convergence Divergence (MACD) is at 0.90, which suggests that PLTR has had strong upward momentum in the past months. The Average True Range (ATR) is 5.16, which points to high volatility. With a stop-loss placed at $18.90 and support near the $18.89 level, these areas could represent potential bounce points if the stock retraces further. The next resistance level to watch is at $19.94, which could limit upward movements in the immediate future.

Fundamental Analysis

Fundamentally, Palantir posted impressive recent results, securing its 4th consecutive quarter of GAAP profitability. The company boasts a 17% year-over-year revenue growth, showcasing solid financial health. However, the stock's price-to-earnings (PE) ratio is at a lofty 282.86, which may raise concerns over valuation among some investors.

News of Palantir's recent contract with the UK's NHS to create its Federated Data Platform underscores the company's widening moat in big data analytics. This contract, reportedly valued at £480 million, marks a significant influx of guaranteed revenue over the next five years and highlights Palantir's diversification from its traditional government contracts into healthcare.

Palantir The analyst community shows a mixed sentiment, with a consensus target indicating a 'Buy' recommendation, but with a spread between a high target of $25 and a low of $4.50, and a consensus target price at $11. Considering the stock's current trading at $19.80, this suggests that analysts are expecting the stock price to adjust downwards in the medium term.

Predictions for Upcoming Trading Day and Week

Considering the recent pullback, overbought RSI, and high volatility, PLTR might experience more short-term selling pressure as traders lock in gains from its recent rally. However, the strong fundamental backdrop may provide support to the stock price. Given the current market dynamics and recent news, it's possible that PLTR's stock price may exhibit high volatility in the upcoming trading day and throughout the week with potential swings around the identified support and resistance levels.

Overall Evaluation

Taking into account the technical signals of potential overbought conditions coupled with the fundamental aspect of strong revenue growth and new lucrative contracts, the outlook for Palantir Technologies Inc. is cautiously optimistic in the near term. Given the current valuation and the projected consensus target price, however, the stock may not provide considerable upside potential in the medium term as the market digests the company's standing.

Based on this analysis, the verdict on PLTR stock at this juncture would be 'Hold.' Potential investors may wait for a clearer buying opportunity or a stronger sign of sustained upward momentum, while current shareholders might consider holding to see how the company leverages its new contract to generate additional growth. Investors should monitor the stock for stability around its support levels before making additional commitments, while also paying attention to broader market sentiment and any potential shifts in the tech sector or healthcare-related industries Palantir is engaged with.

Check full Palantir forecast and analysis here.
Trusted Broker
Start Your Journey With:
eToro
0% Commission Stock Trading
Follow Other Investors Strategy
Wide variety: Crypto, stocks, ETFs

Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk.